adagrasib
AssetAlso called Krazati, MRTX849
Inhibits mutant KRAS G12C, blocking signaling that drives tumor growth.
- Stage
- Approved
- Modality
- Small molecule
- Target
- KRAS
- 17
- Indications
- 29
- Trials
- 1
- Developer
Approved by the FDA on Dec 12, 2022 (NDA216340). 2 approvals stand. FDA
Indications
17Non-small cell lung cancer
Approved, FDA
Advanced non small cell lung cancer
Approved, EMA
Locally advanced or metastatic colorectal cancer with KRAS G12C mutation
Approved, FDA
14 more
In the full profile
- Target and mechanism1
- Owner and partners2
- Trials29
- Evidence for its targets1
- Competitors12
- Signals11
Every asset’s record: target, stage, trials and the evidence behind it.